Shares of Celsion Corporation (NASDAQ:CLSN) gapped up prior to trading on Tuesday . The stock had previously closed at $1.93, but opened at $2.00. Celsion Corporation shares last traded at $2.14, with a volume of 3071400 shares traded.
A number of analysts have recently weighed in on CLSN shares. Maxim Group raised Celsion Corporation from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research report on Wednesday, October 4th. Zacks Investment Research raised Celsion Corporation from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research report on Tuesday, August 29th. Oppenheimer Holdings, Inc. assumed coverage on Celsion Corporation in a research report on Tuesday. They issued an “outperform” rating and a $9.00 price objective for the company. Finally, ValuEngine raised Celsion Corporation from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $11.90.
An institutional investor recently bought a new position in Celsion Corporation stock. Sabby Management LLC acquired a new stake in Celsion Corporation (NASDAQ:CLSN) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 108,843 shares of the biotechnology company’s stock, valued at approximately $223,000. Sabby Management LLC owned 1.30% of Celsion Corporation as of its most recent SEC filing. 6.41% of the stock is currently owned by hedge funds and other institutional investors.
Celsion Corporation Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with MarketBeat.com's FREE daily email newsletter.